

Chapter 9

Increased migration by stimulation of thymidine phosphorylase in endothelial cells of different origin

Nucleotides, Nucleosides and Nucleic Acid, in press

Irene V. Bijnsdorp¹

Kim Vrijland¹

Laura Vroling¹

Masakazu Fukushima²

Godefridus J. Peters¹

1. Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

2. Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan

ABSTRACT

Thymidine phosphorylase (TP) catalyzes the phosphorylytic cleavage of thymidine to thymine and deoxyribose-1-phosphate. The latter may be involved in the angiogenic stimulation of TP. In the present study, we investigated whether thymidine and deoxyribose (dR) could stimulate angiogenesis *in vitro* of two types of endothelial cells (isolated from umbilical veins (HUVEC) and endothelial colony forming cells (ECFC)), and whether the stereoisomer L-deoxyribose (L-dR) and the thymidine phosphorylase inhibitor (TPI) could reduce this. Both cell types had a low TP activity. Thymidine increased the migration of both HUVECs and ECFCs, but dR only that of the ECFCs. The invasion was not changed by any of the agents tested. In conclusion, TP may play a role in the migration of HUVECs and ECFCs, but not the invasion.

INTRODUCTION

The platelet derived endothelial cell growth factor (PD-ECGF) is also known as thymidine phosphorylase (TP). TP is overexpressed in a wide variety of solid tumors¹. TP is an angiogenic factor and was shown to stimulate angiogenesis in various studies. In addition, a high TP in cancer cells may change its invasive characteristic². TP converts thymidine (TdR) to thymine and deoxyribose-1-phosphate (dR-1-P). dR-1-P can be further converted to deoxyribose (dR), which is thought to be the compound by which TP acts as an angiogenic stimulator. Angiogenesis is often studied using endothelial cells derived from human umbilical veins (HUVECs), but more recently it was hypothesized that new blood vessels might also be formed from circulating endothelial (progenitor) cells (EPC)³, rather than from out existing blood vessels. EPCs are cells that are thought to originate from the bone marrow, which can differentiate into endothelial cells and are thought to contribute to neovascularization^{3,4}. In the present study, we used Endothelial Colony Forming Cells (ECFCs)^{5,6} as a model for EPCs and determined whether TP expression in the HUVECs and ECFCs was important for their angiogenic potential. Therefore, we determined the TP enzymatic activity of these cells, the migration and invasion capacity after stimulation of TP with TdR, with the reducing sugar dR and the inhibitors L-dR and TPI.

MATERIALS AND METHODS

Cells

Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cords as described previously⁷ and were cultured in M199 medium, supplemented with 10% FCS (PAA laboratory GmbH, Cölbe Germany), 10% human serum (HS) and ECGF. ECFCs were isolated from mononuclear cells that were obtained from the cord blood, diluted 1:3 with PBS (Phosphate buffered saline, B. Braun, Germany), using Ficoll Paque density gradient separation medium (GE Healthcare Bio-sciences AB, Sweden) and Leucosep 50 mL tubes (Greiner bio-one, Melsungen, Germany). The mononuclear cells were cultured in a concentration of 2.5×10^6 cells per cm^2 in EBM-2 complete medium (Endothelial cell basal medium-2, Lonza, Walkersville, USA) supplemented with 0.1% pen-strep (Lonza, Verviers, Belgium), 10% FCS and EGM-2 SingleQuotes without hydrocortisone and gentamycin/amphotericin-B (Lonza, Walkersville, USA). When the colonies started to appear (after 10-15 days) ECFCs were trypsinized and subcultured into flasks⁸. Subcultured ECFCs showed characteristics of true endothelial cells, such as CD105, CD146, CD31, VE-cadherin, Tie-2, VEGFR1, uptake of AcLDL and UEA binding and CD133, CD14 and CD45 were absent (data not shown). For all experiments with HUVECs and ECFCs, at least 3 different isolations (e.g. donors) were examined for their (angiogenic) response in order to get a reliable result. All cells were maintained in a humidified 5% CO_2 atmosphere at 37°C.

Thymidine phosphorylase activity

The TP activity was determined as described previously⁹. The activity was measured using TdR as a substrate and by detecting the conversion to thymine by HPLC.

Migration assay

Cell migration was determined using the wound healing assay as described previously¹⁰. Cells were grown until confluence and a scratch wound was applied in two perpendicular directions with a sterile pipet tip. Subsequently, cells were washed 2 times with HBSS and cells were exposed to the various agents, diluted in low-serum-medium (5% FCS and 5% HS for HUVECs and 0.1% for ECFCs), corresponding to the cell type used. Wounds were captured at 2.5x magnification with a microscope (TCS 4D, Leica, Jena, Germany), and Q500MC software (Leica) at time points 0 and 6 h. The wound width was measured and compared with the initial width at the 0 h time point (set at 0 %).

Chapter 9

Invasion assay

The invasion assay was carried out as described previously¹⁰, using transwell chambers with a fluorescence-blocking 8 μm pore polycarbonate filter insert (#35-1152; HTS Fluoroblock Insert, Falcon, Becton Dickinson Labware, Bedford, MA) in 24 wells plates (# 35-3504; Falcon, Becton Dickinson). The upper side of the insert was coated overnight at room temperature (RT) with 100 μl matrigel (50 ng/ml in PBS; Sigma). Cells (50 000/insert) were allowed to invade for 8 h (with or without stimulators or inhibitors in the medium corresponding to the cell type). Thirty min before analysis, 5 μM calcein-AM was added to the lower compartment and the amount of fluorescence was measured.

RESULTS AND DISCUSSION

HUVECs had a comparably low TP activity as ECFCs (5.1 ± 0.4 and 5.4 ± 0.6 nmol/million cells/h, respectively), compared to most tested cancer cell lines (varying from 0.6 to 70 nmol/million cells/h)¹¹. This is in agreement with previously reported data for ECFCs and HUVECs¹². In the latter study, TP was found to be a key regulator in angiogenesis induced by ECFCs, both *in vitro* and *in vivo*.

ECFCs are currently being studied in cardiovascular diseases, but because of their capacity to invade into tumor tissues, they also have potential as a target for anti-angiogenic agents in cancer. HUVECs are a widely accepted model to study angiogenesis and are used mostly. HUVECs had a higher migration after 6 h than ECFCs (Figure 1). The migration of HUVECs was increased by TdR and inhibited by TPI and L-dR, although this increase and inhibition were not significant.

Since in HUVECs dR did not stimulate the migration at all, this may indicate that dR might not be the most important factor of TP-mediated HUVEC-migration. dR-1-P formed from TdR can also be isomerized to deoxyribose-5-phosphate, which can subsequently be converted to glyceraldehyde-3-phosphate and enter the pentose phosphate pathway or glycolysis^{13,14}. Possibly, in HUVECs, this pathway might play a role in angiogenesis rather than dR-mediated angiogenesis. On the other hand, ECFC migration was increased to some extent by dR. For these ECFCs, dR might be an important angiogenic factor, since it stimulated the migration¹². It is possible that dR is used for advanced glycation end products (AGE), via Schiff base and/or Maillard reactions¹⁵. dR itself or AGEs may therefore stimulate the cell migration of ECFCs. This indicates that in the two endothelial cell types TdR-derived sugars enter different pathways.

HUVECs and ECFCs had a comparable level of invasion. The invasion was neither stimulated nor inhibited after exposure to TdR, dR, L-dR or TPI (Figure 2). dR has previously been reported to be a good stimulator of migration and invasion of endothelial cells, including HUVECs¹⁶. This stimulation was mediated by activation of intracellular kinases, including the focal adhesion kinase and p70/s6k^{17,18}. Besides dR, other factors may also be involved in TP mediated angiogenesis, such as secretion of IL-8 or VEGF^{19,9}.

In conclusion, these data indicate that the migration of HUVECs and ECFCs can be stimulated by TdR, the substrate for TP and the product dR (for ECFCs). The invasion was not affected by TdR or dR. This low level of stimulation may be related to the low intrinsic TP expression of these cell types.




Figure 1 - Migration of HUVECs and ECFCs after 6 h exposure to 100 μ M TdR, 100 μ M dR, 50 μ M L-dR or 10 μ M TPI. Controls represent the medium with the low % serum, to which TdR, dR, L-dR and TPI were added. All values represent means of at least 4 independent experiments \pm SEM, * $p < 0.05$.




Figure 2 - Invasion of HUVECs and ECFCs after 7 h exposure to 100 μ M TdR, 100 μ M dR, 50 μ M L-dR or 10 μ M TPI. Controls represent the medium with the low % serum, to which TdR, dR, L-dR and TPI were added. All values represent means of at least 3 independent experiments \pm SEM.

REFERENCES

- 1 Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. *Med Res Rev.* 2009;29:903-53.
- 2 De Bruin M, Temmink OH, Hoekman K, Pinedo HM, Peters GJ. Role of platelet derived endothelial cell growth factor/ thymidine phosphorylase in health and disease. *Cancer Therapy* 2006;4:99-124
- 3 Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275:964–967.
- 4 Nolan DJ, Ciarrocchi A, Mellick AS, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. *Genes Developm* 2007;21:1546-58.
- 5 Huang L, Hou D, Thompson MA, Baysden SE, Shelley WC, Ingram DA, March KL, Yoder MC. Acute myocardial infarction in swine rapidly and selectively releases highly proliferative endothelial colony forming cells (ECFCs) into circulation. *Cell Transplant.* 2007;16:887-97.
- 6 Javed MJ, Mead LE, Prater D, Bessler WK, Foster D, Case J, Goebel WS, Yoder MC, Haneline LS, Ingram DA. Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. *Pediatr Res.* 2008;64:68-73.
- 7 Van Hinsbergh VW, Draijer R. Culture and characterization of human endothelial cells. In: Oxford: University Press Shaw A J; 1996. p. 87–110.
- 8 Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, Gillebert TC, Plum J, Vandekerckhove B. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. *Arterioscler Thromb Vasc Biol.* 2007;27:1572-9.
- 9 De Bruin M, Peters GJ, Oerlemans R, Assaraf YG, Masterson AJ, Adema AD, Dijkmans BA, Pinedo HM, Jansen G. Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells. *Mol Pharmacol.* 2004;66:1054-60.
- 10 Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. *Mol Cancer Ther.* 2006;5:2348-57.
- 11 De Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. *Br J Cancer.* 2003;88:957-64.
- 12 Pula G, Mayr U, Evans C, Prokopi M, Vara DS, Yin X, Astroulakis Z, Xiao Q, Hill J, Xu Q, Mayr M. Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. *Circ Res.* 2009;104:32-40.
- 13 Sgarrella F, Poddie FP, Meloni MA, Sciola L, Pippia P, Tozzi MG. Channelling of deoxyribose moiety of exogenous DNA into carbohydrate metabolism: role of deoxyriboaldolase. *Comp Biochem Physiol B Biochem Mol Biol.* 1997;117:253-7
- 14 Sgarrella F, Del Corso A, Tozzi MG, Camici M. Deoxyribose 5-phosphate aldolase of *Bacillus cereus*: purification and properties. *Biochim Biophys Acta.* 1992;1118:130-3.
- 15 Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. *Cancer Res.* 2000;60:6298-302
- 16 Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. *Cancer Res.* 2003;63:527-33.
- 17 Hotchkiss KA, Ashton AW, Schwartz EL. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. *J Biol Chem.* 2003;278:19272-9.
- 18 Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ, Wagner C, Frank E, Jauch KW, Geissler EK. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. *Clin Cancer Res.* 2004;10:1843-52.
- 19 Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. *Cancer Res.* 2000;60:6298-302.